News Sentiment

VERU sentiment intelligence

Veru Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 36 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.78 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 28

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-9.2% over one week, -7.3% over four weeks, trend active, and below fair value.

Latest direct headline Positive

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction -9.2% Price reacting lower
Trend fit Trend active -7.3% over four weeks
Fair value -55.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 27
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 28
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 7
Market source 6
TradingKey 4
Stock Titan 3
simplywall.st 3
Finviz 2
GlobeNewswire 1
Investing.com Canada 1

Event Lens

What the news is about

Classified themes
Earnings 15
Market update 15
Analyst action 3
Macro sensitivity 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 36
GlobeNewswire Direct company coverage

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

Veru Inc. announced it will present at the 2026 4th Annual Obesity & Weight Loss Drug Development Summit and its Pre-Conference Workshop Day in Boston, Massachusetts. Dr. Mitchell Steiner will present on "Combating Sarcopenic Obesity in Geriatrics," and Dr. Gary Barnette will lea

Tone
Positive 74/100
Event
Market update
Published
08 Jul 2026 12:10
Source
GlobeNewswire
TradingView Direct company coverage

Enterprise value to EBIT forward of Veru Inc. – NASDAQ:VERU

This article provides a financial metric, the enterprise value to EBIT forward, for Veru Inc. (NASDAQ:VERU). The content focuses on presenting this specific data point for the pharmaceutical company. The page also includes numerous navigation and information sections typical of a

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 12:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Veru Inc. – NASDAQ:VERU

The article focuses on the "Price to sales forward" metric for Veru Inc. (NASDAQ: VERU), a pharmaceutical company. It presents this financial data point within the context of TradingView's platform, indicating that the value and change for this period are "Made by humans" and tha

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 12:09
Source
TradingView
Investing.com Canada Direct company coverage

Form 424B5 Veru Inc For: 2 July By Investing.com

This article reports on the filing of Form 424B5 by Veru Inc. for July 2nd, as noted by Investing.com. The brief announcement provides no further details but is accompanied by real-time market data for various indices, commodities, and individual stocks. It appears to be a standa

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 08:40
Source
Investing.com Canada
Bitget Direct company coverage

According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Veru Inc. officially signed a sales agreement with Oppenheimer & Co. and Canaccord Genuity on July 2, 2026.

Veru Inc. has officially signed a sales agreement with Oppenheimer & Co. and Canaccord Genuity on July 2, 2026, as per SEC filings. This agreement aims to provide greater flexibility for Veru's future financing activities and may involve the sale of common shares to optimize its

Tone
Positive 65/100
Event
Market update
Published
02 Jul 2026 21:10
Source
Bitget
Finviz Direct company coverage

VERU - Veru Inc Volatility & Greeks

This article provides a detailed financial overview of Veru Inc. (VERU), including its volatility, Greek values, key financial metrics, stock performance, and insider/institutional ownership. It highlights the company's current stock price, market capitalization, earnings per sha

Tone
Negative 40/100
Event
Earnings
Published
02 Jul 2026 20:11
Source
Finviz
Stock Titan Direct company coverage

Veru Inc. (NASDAQ: VERU) to sell up to $21.8M in common stock via ATM

Veru Inc. has registered an at-the-market (ATM) offering to sell up to $21.8 million of its common stock through Oppenheimer & Co. Inc. and Canaccord Genuity LLC. This offering falls under Veru’s existing Form S-3 shelf registration, which has a total capacity of $200 million. Th

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:10
Source
Stock Titan
marketscreener.com Direct company coverage

Veru Inc.(NasdaqCM: VERU) added to Russell Microcap Index

Veru Inc. (NasdaqCM: VERU) has been added to the Russell Microcap Index. This inclusion means Veru Inc. is now part of a broader benchmark that tracks the micro-cap segment of the U.S. equity market, potentially increasing its visibility among investors. The company, a late clini

Tone
Positive 82/100
Event
Market update
Published
29 Jun 2026 19:39
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Veru Inc.(NasdaqCM: VERU) added to Russell Microcap Value Benchmark Index

Veru Inc. (NasdaqCM: VERU), a late clinical-stage biopharmaceutical company, has been added to the Russell Microcap Value Benchmark Index. This inclusion highlights the company's progress, which focuses on developing treatments for metabolic diseases, oncology, and acute respirat

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 12:41
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to revenue forward of Veru Inc. – NASDAQ:VERU

This article displays the "Enterprise value to revenue forward" metric for Veru Inc. (NASDAQ: VERU) on TradingView. It provides financial data for the company within the health technology and pharmaceuticals sector. The content focuses on presenting this specific financial valuat

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 13:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Veru Inc – GETTEX:FMW0

This article provides financial data for Veru Inc (FMW0) on GETTEX, specifically focusing on its enterprise value to revenue forward metric. It indicates that the company's financial overview and related metrics are available, with data provided by ICE Data Services and FactSet.

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 21:41
Source
TradingView
Finviz Direct company coverage

VERU - Veru Inc Latest SEC Filings

This article provides the latest SEC filings and a comprehensive financial overview for Veru Inc. (VERU), as of July 1, 2026. It includes detailed financial metrics, performance indicators, insider ownership, institutional ownership, and analyst recommendations. The data indicate

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 19:39
Source
Finviz
TradingView Direct company coverage

Veru Inc Actuals & Estimates (NASDAQ:VERU)

This article provides an overview of Veru Inc. (NASDAQ:VERU) stock performance, financials, and analyst forecasts. It includes details on the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates, along with insights into p

Tone
Positive 61/100
Event
Earnings
Published
25 Jun 2026 19:09
Source
TradingView
TradingView Direct company coverage

VERU Forecast — Price Target — Prediction for 2027

This article provides a forecast for Veru Inc. (VERU) stock, including analyst price targets, past performance, and key financial data. It highlights that two analysts offer price forecasts with a max estimate of $25.00 and a min estimate of $24.00, while the stock currently trad

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 13:41
Source
TradingView
TradingKey Direct company coverage

Veru Inc (VERU) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Veru Inc (VERU), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. While the stock's price momentum score is 6.97, ranking it 177 out of 387 in its industry, tec

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 04:41
Source
TradingKey
TradingKey Direct company coverage

Veru Inc (VERU) Earnings Forecast: Future EPS & Revenue Growth Estimates

Veru Inc. (VERU) has an earnings forecast score of 9.00, placing it 16th in its industry, with analysts giving it a strong buy rating and a target price of $22.50. The company's stock is currently trading at $2.95, and its previous quarter's EPS was -$0.26, below the market expec

Tone
Positive 72/100
Event
Earnings
Published
18 Jun 2026 14:09
Source
TradingKey
TradingKey Direct company coverage

Veru Inc (VERU) Institutional Confidence

Veru Inc (VERU) currently holds an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 37.93% quarter-over-quarter, reaching 28.10%. James Simons is iden

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 02:40
Source
TradingKey
TradingKey Direct company coverage

Veru Inc (VERU) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Veru Inc (VERU), noting its stock price, market capitalization, and current P/E ratio. The company's valuation score is 8.20, ranking it 163 out of 388 in the Biotechnology & Medical Research industry. Key financial metrics such as P

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 01:39
Source
TradingKey
Investing.com Direct company coverage

Why is Veru stock rising 10% today?

Veru Inc. stock surged 10% following a clinical supply agreement with Novo Nordisk for its Phase 2b PLATEAU trial, granting Novo Nordisk a right of first negotiation for a potential enobosarm licensing deal. This agreement, combined with strong analyst ratings, improved Q2 fiscal

Tone
Neutral 50/100
Event
Analyst action
Published
11 Jun 2026 16:09
Source
Investing.com
Sahm Direct company coverage

Novo Nordisk Wegovy Trial With Veru Adds Underappreciated Obesity Angle

Novo Nordisk has partnered with Veru Inc. in a clinical supply agreement to provide Wegovy for a Phase 2b obesity trial in older adults, focusing on combination therapy. This collaboration is considered an underappreciated development by investors, as it is outside Novo Nordisk’s

Tone
Neutral 50/100
Event
Macro sensitivity
Published
06 Jun 2026 21:10
Source
Sahm